https://www.selleckchem.com/products/yo-01027.html
The COVID-19 pandemic has made it necessary to find innovative strategies that facilitate safe, private assessment and intervention for intimate partner violence (IPV). IPV is a major source of morbidity and mortality, with women experiencing a lifetime prevalence rate of 22%. Screening pregnant individuals for IPV during the COVID-19 pandemic became critical because a 20% rise in IPV during the pandemic has been estimated. A multidisciplinary stakeholder panel created a process using technology to address this concern. An infographic
Like
Comment
Share
